Insider Selling: BeOne Medicines (NASDAQ:ONC) COO Sells $2,286,664.86 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 6,009 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $380.54, for a total value of $2,286,664.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, November 12th, Xiaobin Wu sold 10,000 shares of BeOne Medicines stock. The shares were sold at an average price of $356.02, for a total value of $3,560,200.00.

BeOne Medicines Price Performance

NASDAQ ONC opened at $365.82 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The stock has a market cap of $43.36 billion, a price-to-earnings ratio of 717.29 and a beta of 0.31. The business has a 50 day simple moving average of $329.90 and a 200 day simple moving average of $291.98. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $381.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ONC. Creative Planning raised its stake in shares of BeOne Medicines by 49.7% during the 3rd quarter. Creative Planning now owns 8,951 shares of the company’s stock worth $3,050,000 after purchasing an additional 2,970 shares in the last quarter. Lazard Asset Management LLC increased its holdings in BeOne Medicines by 74.7% during the third quarter. Lazard Asset Management LLC now owns 41,380 shares of the company’s stock worth $14,098,000 after buying an additional 17,688 shares during the last quarter. Raymond James Financial Inc. raised its position in BeOne Medicines by 4.2% during the third quarter. Raymond James Financial Inc. now owns 17,196 shares of the company’s stock worth $5,859,000 after acquiring an additional 693 shares in the last quarter. Qtron Investments LLC raised its position in BeOne Medicines by 12.4% during the third quarter. Qtron Investments LLC now owns 3,742 shares of the company’s stock worth $1,275,000 after acquiring an additional 412 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in BeOne Medicines in the third quarter valued at $1,052,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ONC has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, October 8th. Royal Bank Of Canada upped their price objective on BeOne Medicines from $374.00 to $395.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Citigroup upped their price target on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Guggenheim raised their price target on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $357.33.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.